|Systematic (IUPAC) name|
|Mol. mass||362.94 g/mol|
|(what is this?)|
Viminol (marketed under the brandname Dividol) is an opioid analgesic developed by the drugs company Zambon in the 1960s. It has an unusual chemical structure that is not similar to other opioids.
Viminol has both antitussive (cough suppressing) and analgesic (pain reducing) effects. It has six different stereoisomers which have varying properties. 4 are inactive, the 2-(R)N,N-(S) isomer being a μ-opioid full agonist around 5.5 times more potent than morphine while the 2-(S)-N,N-(R) isomer is an antagonist. Since vimonol is supplied as a racemic mixture of isomers, the overall effect produces a mixed agonist–antagonist profile similar to that of opioids such as pentazocine, although with somewhat fewer side effects.
Side effects are similar to other opioids, and can include:
However, since viminol is supplied as a racemic mixture of agonist and antagonist isomers, the abuse potential and respiratory depression tends to be less than that of μ-opioid full agonist drugs.
- US patent 3539589, Uberto M Teotino and Davide Della Bella, "1-(α-PYRRYL)-2-AMINO ETHANOLS", published 1967-05-08, issued 1970-10-11
- Contri AM. Chromatographic separation of diastereoisomers of aminoalcohol salts and their densitometric determination. (Italian). Il Farmaco. 1981 Apr;36(4):215-22.
- Neto JM, Murad JE, Monteiro SS. Psychopharmacological properties of the viminol-p-hydroxybenzoate. Revista Brasileira de Pesquisas Medicas e Biologicas. 1977 Dec;10(6):361-8.
- US Patent 3857857 - Davide Della Bella, Carlo Veneziani Bresso, Dario Chiarnio Monza & Uberio Maria Tiotino 'Stereoisomers of 1(1'(-O-Chlorobenzyl)-2'-Pyrryl)-2-Disec.Butylamino-Ethanol'
- Shook JE, Kallman MJ, Dewey WL. The discriminative stimulus properties of the R2 isomer of viminol. Pharmacology, Biochemistry and Behaviour. 1984 Jan;20(1):59-62.
- Cinelli M, Costa V, Ventresca GP, Lodola E. Viminol R2 analgesic activity in patients with postoperative pain: comparison with pentazocine. International Journal of Clinical Pharmacology, Therapy and Toxicology. 1986 May;24(5):232-5.